12月31日，天眼查融资历程显示，苏州易合医药有限公司近日获得"B轮"融资，涉及融资金额近亿人民 币，投资机构为北京市医药健康产业投资基金，三泽创投。 天眼查信息显示，苏州易合医药有限公司的股东为：宁波盈合医药合伙企业（有限合伙）、史楷岐、北 京亦庄二期生物医药产业投资基金（有限合伙）、北京市医药健康产业投资基金（有限合伙）、漳州圆 山大健康产业投资基金合伙企业（有限合伙）。 资料显示，苏州易合医药有限公司法定代表人为史楷岐，成立于2020年，位于苏州市，是一家以从事研 究和试验发展为主的企业。企业注册资本485.5526万人民币，并已于2025年完成了B轮，交易金额近亿 人民币。 来源：市场资讯 通过天眼查大数据分析，苏州易合医药有限公司共对外投资了6家企业，知识产权方面有商标信息21 条，专利信息66条，此外企业还拥有行政许可2个。 ...

Meeting Overview - The 34th meeting of the 9th Board of Directors of China Pharmaceutical Health Industry Co., Ltd. was held on December 29, 2025, combining in-person and communication methods, chaired by Chairman and General Manager Yang Guang [2] - All 8 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and the Articles of Association, making the resolutions valid [4][5] Resolutions Passed - The board approved the proposal to acquire 70% equity of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for a cash consideration of 525 million RMB [6][14] - The board also approved the revision of the "System Management Measures" [8][9] Transaction Details - The acquisition aims to enhance the company's comprehensive strength in pharmaceutical research and development, addressing current shortcomings in its R&D system and achieving a full industry chain from research to production [18] - The total transaction amount is 525 million RMB, funded by the company's own and/or self-raised funds [18] - After the transaction, the company will hold 70% of Zezheng Pharmaceutical, which will become a subsidiary included in the company's consolidated financial statements [18] Financial Overview of the Target Company - As of September 30, 2025, Zezheng Pharmaceutical had total assets of 421.63 million RMB and net assets of 264.62 million RMB, with a revenue of 107.29 million RMB and a net loss of 40.85 million RMB for the first nine months of 2025 [47] - The valuation of Zezheng Pharmaceutical was assessed at 758.84 million RMB using the income approach, indicating a significant increase in value [48] Strategic Importance of the Transaction - The acquisition is expected to strengthen the company's position in the pharmaceutical R&D sector, allowing for deeper integration of technology, market, and resources, and enhancing competitiveness [63] - The management of Zezheng Pharmaceutical will be arranged according to the agreement, ensuring the company's legal rights and control [63]

Core Insights - China Medical (600056.SH) announced the acquisition of 70% stake in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for RMB 525 million, marking a significant step in enhancing its R&D capabilities and integrating the entire industry chain from R&D to production [1][2] Group 1: Acquisition Details - The acquisition will allow Zezheng Pharmaceutical to become a subsidiary of China Medical, thus included in its consolidated financial statements [1] - Zezheng Pharmaceutical, established in 2017, specializes in modified new drugs and complex formulations, with over 100 R&D projects submitted to the National Medical Products Administration and 55 drug approvals obtained [1] Group 2: Strategic Implications - The acquisition aims to fill the gaps in China Medical's capabilities in generic drugs, modified new drugs, and innovative drugs, facilitating the upgrade of its product pipeline [1] - By combining Zezheng Pharmaceutical's CRO services with China Medical's industrial capacity, the transaction is expected to accelerate the conversion of technological achievements and create a competitive edge in high-barrier areas like complex formulations [1] - The retention of Zezheng Pharmaceutical's core team post-acquisition is intended to ensure operational stability [1] Group 3: Industry Context - Industry experts highlight that in the context of national encouragement for pharmaceutical innovation and the normalization of generic drug consistency evaluations, CRO companies with comprehensive R&D capabilities and differentiated technology platforms hold unique advantages [2] - The integration of resources through this acquisition is anticipated to foster a collaborative ecosystem of "R&D—Manufacturing—Commercialization," enhancing overall competitiveness [2]

Core Viewpoint - China Medical (600056.SH) aims to enhance its comprehensive strength in pharmaceutical R&D innovation by acquiring a 70% stake in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for RMB 525 million, thereby addressing current R&D system shortcomings and integrating the entire industry chain from R&D to production [1] Group 1 - The acquisition will be funded through the company's own and/or self-raised funds [1] - After the transaction, Zezheng Pharmaceutical will become a wholly-owned subsidiary of China Medical, included in the consolidated financial statements [1] - This move is expected to strengthen the company's capabilities in pharmaceutical R&D, facilitating deep integration in technology, market, and resources [1] Group 2 - The transaction aims to enhance the company's layout in various fields, including generic drug research, improved new drug research, and innovative drug research [1] - The integration is intended to create a collaborative development framework among pharmaceutical R&D, industrial production, and commercial operations [1] - This strategic acquisition is anticipated to further improve the competitiveness of the listed company in the pharmaceutical industry [1]

Group 1 - The core point of the article is that China Medical (600056.SH) announced the acquisition of a 70% stake in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for a total amount of RMB 525 million [1] - The acquisition was approved during the 34th meeting of the 9th Board of Directors held on December 29, 2025 [1] - Shanghai Zezheng Pharmaceutical, established in 2017, specializes in the research and development of modified new drugs and complex formulations, providing a full range of R&D services including drug research, clinical trials, and registration applications [1]

Core Viewpoint - The company has signed a share purchase agreement to acquire 70% of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for a cash investment of 525 million RMB, aiming to enhance its capabilities in pharmaceutical R&D innovation and address current shortcomings in its R&D system [1] Group 1: Transaction Details - The total cash investment for the acquisition is 525 million RMB [1] - The transaction involves 13 counterparties who collectively hold the shares being purchased [1] - The acquisition will result in Shanghai Zezheng becoming a wholly-owned subsidiary of the company [1] Group 2: Strategic Objectives - The primary goal of the transaction is to strengthen the company's overall strength in the pharmaceutical R&D innovation sector [1] - The acquisition is intended to bridge the gap in the current R&D system and facilitate a full industry chain from research and development to production [1] - The transaction has been approved by the board of directors and does not require shareholder approval [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券简称：688222 证券代码：成都先导 公告编号：2025-058 成都先导药物开发股份有限公司 关于募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则（2025年4月修订）》《上 海证券交易所科创板上市公司自律监管指引第 1 号一一规范运作（2025年5月修订）》等相关规定，成 都先导药物开发股份有限公司（以下简称"成都先导"或"公司"）于 2025 年 12 月 25 日召开第三届董事 会第四次会议，审议通过了《关于募集资金投资项目延期的议案》。同意公司结合目前募集资金投资项 目的实际建设情况和投入进度，在募集资金投资项目实施主体、实施方式、投资用途及投资规模不发生 变更的情况下，对"新分子设计、构建与应用平台建设项目"、"新药研发中心建设项目"达到预定可使用 状态的时间进行调整。上述募集资金投资项目对应的建筑主体工程已顺利通过基础结构验收、顺利完成 封顶，调整后项目实施期限 ...

Economic News - The People's Bank of China emphasizes the continuation of a moderately loose monetary policy to promote stable economic growth and reasonable price recovery [2] - The State Administration for Market Regulation issues a plan for the special governance of the quality and safety of industrial products sold online from 2025 to 2027 [2] - In November, China's total electricity consumption reached 835.6 billion kWh, a year-on-year increase of 6.2%, with high-tech and equipment manufacturing industries seeing a 6.7% increase [2] - The Ministry of Commerce announces increased policy support for foreign trade innovation and development [2] - The Chinese Foreign Ministry firmly opposes the U.S. plans to impose tariffs on China's semiconductor industry starting in 2027 [2] - Beijing's housing authorities relax home purchase conditions for non-local families and support housing needs for families with multiple children [2] Company News - Springlight Technology receives OEM/ODM orders for "W1" and "M1" robot products from Lexiang Technology, amounting to 43.2628 million yuan [3] - Wankai New Materials' subsidiary, Qing Magnesium Smart Plastic, signs a procurement contract with Lingxin Qiaoshou for lightweight components and assembly services, totaling 10 million yuan [3] - Nanshan Aluminum establishes a wholly-owned subsidiary in Hainan with an investment of 5 million yuan to expand high-end aluminum product development and trade [3] - Sunshine Nuohuo signs a technology development contract with Zhejiang Xinghao, with a total payment of 500 million yuan, including an 8% sales share [5] - Jiaheng Home Products' controlling shareholder is planning a change in control, leading to a temporary suspension of trading [5] Industry Research Agriculture and Animal Husbandry - The Ministry of Commerce announces anti-dumping duties on EU pork imports, effective from December 17, 2025, with rates ranging from 4.9% to 19.8% [6] - EU pork imports account for 51% of China's total pork imports, but only 2.03% of total consumption, indicating a limited impact on overall supply [7] - The anti-dumping duties are expected to increase the cost of EU pork imports, leading to a decrease in import volumes and a diversification of import sources [7] - Despite the anti-dumping measures, domestic supply and demand dynamics will continue to influence pork prices, with an oversupply expected to persist [8] - The report recommends focusing on leading companies in the pig farming industry, such as Muyuan Foods, as the market dynamics improve [8] Food and Beverage - The Chinese Ministry of Commerce initiates temporary anti-subsidy measures on EU dairy products, with preliminary subsidy rates between 28.6% and 42.7% [10][11] - The affected dairy products include cream and cheese, which have significantly impacted domestic producers' profitability [12] - The average price of fresh milk in China remains low at 3.03 yuan/kg, putting pressure on dairy companies [13] - The anti-subsidy measures are expected to create market opportunities for domestic dairy processing companies, benefiting firms like Lihai and Miao Ke Landuo [13]

Group 1 - The company, along with several partners, has established a partnership agreement to form a new enterprise with an initial investment of RMB 227.27 million [1] - The investment contributions from the partners include RMB 70 million from the company, RMB 30 million from Taimei Zhiyan, RMB 100 million from Jiaxing Chantuo, and smaller amounts from individual partners [1] - The partnership will prioritize investments in companies located in the Jiaxing Economic and Technological Development Zone [1] Group 2 - The board believes that the establishment of the partnership will enable deep participation in the research and development of innovative drug pipelines, allowing the company to standardize and modularize its digital pharmaceutical R&D solutions [2] - The partnership will hold pipeline rights and participate in early clinical trials, aiming to capture key segments of the industry value chain while avoiding the complexities and long-term risks associated with traditional equity investments [2] - The company anticipates efficient exits through the transfer or sale of pipeline rights, facilitating rapid capital turnover and value realization [2]

Core Viewpoint - The company, Sunlight Nuohe (688621.SH), has signed a technology development contract with Zhejiang Xinghao Holding Partnership (Limited Partnership) to jointly develop the STC008 injection project, which is expected to positively impact the company's future performance and enhance profitability [1] Financial Summary - The company will receive an initial payment of 50 million yuan and subsequent milestone payments, totaling 500 million yuan (including tax), along with an 8% share of net sales [1] Project Status - The STC008 project is currently in Phase I clinical trials, indicating a long development cycle and multiple risks related to the research and market environment [1]